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128 Dyella species − a new opportunistic pathogen or an innocent
bystander in cystic ﬁbrosis?
L.M. Duus1, M. Wang1, O. Schiøtz2, N. Nørskov-Lauritsen1. 1Aarhus University
Hospital, Department of Clinical Microbiology, Aarhus, Denmark; 2Aarhus
University Hospital, Department of Paediatrics, Aarhus, Denmark
Objective: To describe Dyella species associated with cystic ﬁbrosis (CF).
Methods: Phenotypic identiﬁcation by VITEK-2; mass spectrometry; 16S rDNA
sequencing; minimal inhibitory concentration by Etest® and categorisation as
susceptible (S) or resistant (R) according to EUCAST interpretative criteria for
Pseudomonas.
Results: An oxidase-positive Gram-negative rod was isolated on Burkholderia
cepacia selective agar in May 2009. Initially the bacterium was identiﬁed by
VITEK-2 as Elizabethkingia meningoseptica, however subsequent 16S rRNA gene
sequencing revealed it belonged to genus Dyella. Only one single human infection
with Dyella (bacteremia in a hemodialysis patient) has been described previously.
Dyella species was cultured from this patient in 5 of 11 sputum samples during
2010, and from 8 of 10 specimens in 2011, rendering the patient chronically
infected when applying the “Leeds criteria” often used for Pseudomonas aeruginosa
infection.
An unusual antibiotic susceptibility pattern was observed: piperacillin–tazobactam,
3mg/L (S); meropenem, >32mg/L (R); fosfomycin, 256mg/L (R); ciproﬂoxacin,
3mg/L (R); moxiﬂoxacin, 0.25mg/L (no breakpoint); tobramycin, 3mg/L (S);
colistin, >256mg/L (R).
A unique MALDI-TOF mass spectrum was displayed, and the strain is easily
recognised by mass spectrometry after the generation of reference spectra.
The patient experienced a steep decline in FEV1 (approx. 4%/year) for several years
prior to and after colonisation with Dyella.
Conclusion: Bacteria of genus Dyella can colonise the CF lung and pose a diag-
nostic challenge for the clinical microbiology laboratory. The clinical signiﬁcance
of the colonisation is unknown.
129 Beneﬁts of testing multiple isolates of Staphylococcus aureus
isolated from the sputa of patients with cystic ﬁbrosis
K. Hill1, A. Nicholson1, A. Kearns2, T. Carroll1, S. Bourke1, A. Robb1.
1Freeman Hospital, Microbiology, Newcastle upon Tyne, United Kingdom; 2Health
Protection Agency, Laboratory of Healthcare Associated Infections, Collindale,
United Kingdom
Objective: Cystic ﬁbrosis (CF) patients are highly susceptible to colonisation by
Staphylococcus aureus and can suffer repeated infections. It is known that CF
patients are often colonised by more than one strain of S. aureus. What is less
well established is whether co-colonisation by multiple strains has consequences
for patient care.
Method: SAID agar (bioMerieux) is our routine medium for detection of S. aureus
from CF sputum. Over 4 months 78 S. aureus positive samples from 54 CF patients
were received. Routine culture plates that were positive for S. aureus at 48h were
left at room temperature for a further 24h to enhance variations in pigmentation.
Morphological variants based on colony size, colour and texture were recovered
and identiﬁcations conﬁrmed using MALDI-TOF MS. From these positive samples
122 separate isolates were recovered on the basis of colonial morphology.
A total 59 isolates from 16 patients from whom more than one isolate was recovered
were subjected to mecA PCR, PVL PCR, spa typing and antibiotic susceptibility
testing. Results showed that 8/16 patients possessed S. aureus of more than one
spa type and 4/16 were colonised with more than 1 clonal complex. Antibiotic
proﬁles varied between isolates of single patients. One patient was colonised with
both MRSA and MSSA, one possessed a PVL− and PVL+ strain and 3 patients
were colonised with small colony variants (SCV) as well as isolates with a normal
phenotype. One strain of antibiotic-dependant SCV S. aureus was isolated.
Conclusion: Isolation and testing of a single colony of S. aureus risks missing
clinically signiﬁcant features of colonisation by multiple isolates of S. aureus.
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Background: Long-term low-dose azithromycin (AZM) treatment in cystic ﬁbrosis
(CF) has raised the concern of appearance of resistant microorganisms. Our study
investigates association on meticillin-resistant Staphylococcus aureus (MRSA)
emergence and azithromycin treatment.
Methods: CF patients never MRSA infected prior to inclusion were included in a
retrospective cohort study. Follow up started 2 years prior to treatment up to 3 years
after. MRSA distribution and forced expiratory volume in the ﬁrst second (FEV1)
decline were compared between 19 patients on AZM treatment for at least a year
and 57 age sex matched controls. Microbiological results prior to AZM were also
compared within groups to treatment period using Wilcoxon rank test for paired
variables and logistic regression.
Results: Three (16%) AZM patients compared to 8 (14%) controls had MRSA
positive cultures (p = 0.85). AZM use was not predictive of MRSA isolation, using
Cox regression adjusted for age, FEV1 and gender (p = 0.40). In AZM treated
patients %FEV1 improved in the ﬁrst year after initiation of azithromycin (mean
annual change: −8.2% before versus 3.6% after initiation; p< 0.01) but decreased
during the second third and four years after initiation, to become similar to control
group (−1.25%). There is no association between AZM and Aspergillus fumigatus
infection in this study
Conclusions: MRSA emergence in CF patients is not increased by maintenance
azithromycin therapy. Despite temporary improvement, slope of FEV1 decline
seems not to be decreased by AZM therapy.
131 The clinical implications of MRSA colonisation in a cohort of Irish
adult cystic ﬁbrosis (CF) patients and MRSA carrier frequency
and clinical sequelae in their household contacts
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Objectives: MRSA colonisation in CF has been linked to reduced survival raising
the question of eradication strategies. A single US study highlighted a 14.7% MRSA
colonisation rate in CF household contacts. Our aims were to
1. determine the prevalence of MRSA in an adult Irish CF cohort and correlate
with clinical phenotype,
2. to measure the MRSA carrier frequency in this cohort’s household contacts and
3. to assess for superiority using a molecular detection method.
Methods: MRSA colonisation was determined as 2 sputum samples positive
for MRSA between March 2009 and March 2011 in keeping with international
standards. Clinical phenotype data were recorded from a medical case note review.
MRSA carrier frequency was determined in consenting household contacts (HHC)
with nasal swab cultures and with LightCycler MRSA advanced test ©. HHC also
completed a health questionnaire.
Conclusions: 9 patients (7 male/2 female) met criteria with a 6.97% (n = 9/129)
MRSA prevalence. In CF patients MRSA colonisation was associated with a trend
towards decreased lung function (62% predicted vs 72% predicted) and increased
exacerbation rate over 2 years (1.55 vs 1.46). All HHCs (n = 19) consented to
screening. The prevalence of chronic MRSA colonisation in HHC was 18.7% based
on standard culture and 12.5% based on LightCycler MRSA advanced test ©. None
of the HHC colonised with MRSA had any active medical problems. This is the
ﬁrst study demonstrating MRSA carrier frequency in European HHC and supports
the potential role of eradication in HHC as part of a MRSA eradication strategy in
CF. Our data did not demonstrate superiority using a molecular detection model.
